Links to Exploration step
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Reverse genetics approaches to combat pathogenic arenaviruses</title><author><name sortKey="De La Torre, Juan C" sort="De La Torre, Juan C" uniqKey="De La Torre J" first="Juan C." last="De La Torre">Juan C. De La Torre</name></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">18782590</idno><idno type="pmc">2628465</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2628465</idno><idno type="RBID">PMC:2628465</idno><idno type="doi">10.1016/j.antiviral.2008.08.002</idno><date when="2008">2008</date><idno type="wicri:Area/Pmc/Corpus">000376</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000376</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Reverse genetics approaches to combat pathogenic arenaviruses</title><author><name sortKey="De La Torre, Juan C" sort="De La Torre, Juan C" uniqKey="De La Torre J" first="Juan C." last="De La Torre">Juan C. De La Torre</name></author></analytic><series><title level="j">Antiviral research</title><idno type="ISSN">0166-3542</idno><idno type="eISSN">1872-9096</idno><imprint><date when="2008">2008</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p id="P2">Several arenaviruses cause hemorrhagic fever (HF) in humans, and evidence indicates that the worldwide-distributed prototypic arenavirus lymphocytic choriomeningitis virus (LCMV) is a neglected human pathogen of clinical significance. Moreover, arenaviruses pose a biodefense threat. No licensed anti-arenavirus vaccines are available, and current anti-arenavirus therapy is limited to the use of ribavirin, which is only partially effective and is associated with anemia and other side effects. Therefore, it is important to develop effective vaccines and better antiviral drugs to combat the dual threats of naturally occurring and intentionally introduced arenavirus infections. The development of arenavirus reverse genetic systems is allowing investigators to conduct a detailed molecular characterization of the viral cis-acting signals and trans-acting factors that control each of the steps of the arenavirus life cycle, including RNA synthesis, packaging and budding. Knowledge derived from these studies is uncovering potential novel targets for therapeutic intervention, as well as facilitating the establishment of assays to identify and characterize candidate antiviral drugs capable of interfering with specific steps of the virus life cycle. Likewise, the ability to generate predetermined specific mutations within the arenavirus genome and analyze their phenotypic expression would significantly contribute to the elucidation of arenavirus-host interactions, including the basis of their ability to cause severe HF. This, in turn, could lead to the development of novel, potent and safe arenavirus vaccines.</p></div></front></TEI><pmc article-type="research-article" xml:lang="EN"><pmc-comment>The publisher of this article does not allow downloading of the full text in XML form.</pmc-comment>
<pmc-dir>properties manuscript</pmc-dir>
<front><journal-meta><journal-id journal-id-type="nlm-journal-id">8109699</journal-id><journal-id journal-id-type="pubmed-jr-id">688</journal-id><journal-id journal-id-type="nlm-ta">Antiviral Res</journal-id><journal-title>Antiviral research</journal-title><issn pub-type="ppub">0166-3542</issn><issn pub-type="epub">1872-9096</issn></journal-meta><article-meta><article-id pub-id-type="pmid">18782590</article-id><article-id pub-id-type="pmc">2628465</article-id><article-id pub-id-type="doi">10.1016/j.antiviral.2008.08.002</article-id><article-id pub-id-type="manuscript">NIHMS82405</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Reverse genetics approaches to combat pathogenic arenaviruses</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>de la Torre</surname><given-names>Juan C.</given-names></name><aff id="A1">Immunology and Microbial Science, IMM-6, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, California, 92037, USA, Ph: 858.784.9462 Fax: 858.784.9981<email>juanct@scripps.edu</email></aff></contrib></contrib-group><pub-date pub-type="nihms-submitted"><day>12</day><month>12</month><year>2008</year></pub-date><pub-date pub-type="epub"><day>7</day><month>9</month><year>2008</year></pub-date><pub-date pub-type="ppub"><month>12</month><year>2008</year></pub-date><pub-date pub-type="pmc-release"><day>1</day><month>12</month><year>2009</year></pub-date><volume>80</volume><issue>3</issue><fpage>239</fpage><lpage>250</lpage><abstract><p id="P2">Several arenaviruses cause hemorrhagic fever (HF) in humans, and evidence indicates that the worldwide-distributed prototypic arenavirus lymphocytic choriomeningitis virus (LCMV) is a neglected human pathogen of clinical significance. Moreover, arenaviruses pose a biodefense threat. No licensed anti-arenavirus vaccines are available, and current anti-arenavirus therapy is limited to the use of ribavirin, which is only partially effective and is associated with anemia and other side effects. Therefore, it is important to develop effective vaccines and better antiviral drugs to combat the dual threats of naturally occurring and intentionally introduced arenavirus infections. The development of arenavirus reverse genetic systems is allowing investigators to conduct a detailed molecular characterization of the viral cis-acting signals and trans-acting factors that control each of the steps of the arenavirus life cycle, including RNA synthesis, packaging and budding. Knowledge derived from these studies is uncovering potential novel targets for therapeutic intervention, as well as facilitating the establishment of assays to identify and characterize candidate antiviral drugs capable of interfering with specific steps of the virus life cycle. Likewise, the ability to generate predetermined specific mutations within the arenavirus genome and analyze their phenotypic expression would significantly contribute to the elucidation of arenavirus-host interactions, including the basis of their ability to cause severe HF. This, in turn, could lead to the development of novel, potent and safe arenavirus vaccines.</p></abstract><contract-num rid="AI1">U54 AI065359-040007</contract-num><contract-num rid="AI1">R01 AI047140-06A1</contract-num><contract-sponsor id="AI1">National Institute of Allergy and Infectious Diseases Extramural Activities : NIAID</contract-sponsor></article-meta></front></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/CovidV1/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000376 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 000376 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= CovidV1
|flux= Pmc
|étape= Corpus
|type= RBID
|clé=
|texte=
}}
| This area was generated with Dilib version V0.6.33. |  |